Background: Antipsychotic agents are often used to treat neuropsychiatric symptoms (NPS) in people with dementia although there is uncertainty about the effectiveness of their long-term use for this indication and concern that they may cause harm, including higher mortality. When behavioural strategies have failed and treatment with antipsychotic drugs is instituted, regular attempts to withdraw them have been recommended in guidelines. Physicians, nurses and families of older people with dementia may be reluctant to stop antipsychotics, fearing deterioration of NPS.This is an update of a Cochrane Review published in 2013.
Objectives: To evaluate whether withdrawal of antipsychotic agents is successful in older people with dementia and NPS in primary care or nursing home settings, to list the different strategies for withdrawal of antipsychotic agents in older participants with dementia and NPS, and to measure the effects of withdrawal of antipsychotic agents on participants' behaviour and assess safety.
Search methods: We searched the Specialized Register of the Cochrane Dementia and Cognitive Improvement Group (ALOIS), theCochrane Library, MEDLINE, Embase, PsycINFO, CINAHL, LILACS, clinical trials registries and grey literature sources up to 11 January 2018.
Selection criteria: We included all randomised, controlled trials comparing an antipsychotic withdrawal strategy to continuation of antipsychotics in people with dementia who had been treated with an antipsychotic drug for at least three months.
Data collection and analysis: We used standard methodological procedures according to the Cochrane Handbook for Systematic Reviews of Interventions. We rated the quality of evidence for each outcome using the GRADE approach.
Main results: We included 10 studies involving 632 participants. One new trial (19 participants) was added for this update.One trial was conducted in a community setting, eight in nursing homes and one in both settings. Different types of antipsychotics at varying doses were discontinued in the studies. Both abrupt and gradual withdrawal schedules were used. Reported data were predominantly from studies at low or unclear risk of bias.We included nine trials with 575 randomised participants that used a proxy outcome for overall success of antipsychotic withdrawal. Pooling data was not possible due to heterogeneity of outcome measures used. Based on assessment of seven studies, discontinuation may make little or no difference to whether or not participants complete the study (low-quality evidence).Two trials included only participants with psychosis, agitation or aggression who had responded to antipsychotic treatment. In these two trials, stopping antipsychotics was associated with a higher risk of leaving the study early due to symptomatic relapse or a shorter time to symptomatic relapse.We found low-quality evidence that discontinuation may make little or no difference to overall NPS, measured using various scales (7 trials, 519 participants). There was some evidence from subgroup analyses in two trials that discontinuation may reduce agitation for participants with less severe NPS at baseline, but may be associated with a worsening of NPS in participants with more severe NPS at baseline.None of the studies assessed withdrawal symptoms. Adverse effects of antipsychotics (such as falls) were not systematically assessed. Low-quality evidence showed that discontinuation may have little or no effect on adverse events (5 trials, 381 participants), quality of life (2 trials, 119 participants), or cognitive function (5 trials, 365 participants).There were insufficient data to determine whether discontinuation of antipsychotics has any effect on mortality (very low-quality evidence).
Authors' conclusions: There is low-quality evidence that antipsychotics may be successfully discontinued in older people with dementia and NPS who have been taking antipsychotics for at least three months, and that discontinuation may have little or no important effect on behavioural and psychological symptoms. This is consistent with the observation that most behavioural complications of dementia are intermittent and often do not persist for longer than three months. Discontinuation may have little or no effect on overall cognitive function. Discontinuation may make no difference to adverse events and quality of life. Based on the trials in this review, we are uncertain whether discontinuation of antipsychotics leads to a decrease in mortality.People with psychosis, aggression or agitation who responded well to long-term antipsychotic drug use, or those with more severe NPS at baseline, may benefit behaviourally from continuation of antipsychotics. Discontinuation may reduce agitation for people with mild NPS at baseline. However, these conclusions are based on few studies or small subgroups and further evidence of benefits and harms associated with withdrawal of antipsychotic is required in people with dementia and mild and severe NPS.The overall conclusions of the review have not changed since 2013 and the number of available trials remains low.
Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.Cochrane Database Syst Rev. 2013 Mar 28;(3):CD007726. doi: 10.1002/14651858.CD007726.pub2. Cochrane Database Syst Rev. 2013. PMID: 23543555 Review.
Discontinuation of Long-Term Antipsychotic Drug Use for Behavioral and Psychological Symptoms in Older Adults Aged 65 Years and Older With Dementia.J Am Med Dir Assoc. 2018 Nov;19(11):1009-1014. doi: 10.1016/j.jamda.2018.06.023. Epub 2018 Aug 9. J Am Med Dir Assoc. 2018. PMID: 30100234
Valproate preparations for agitation in dementia.Cochrane Database Syst Rev. 2018 Oct 5;10(10):CD003945. doi: 10.1002/14651858.CD003945.pub4. Cochrane Database Syst Rev. 2018. PMID: 30293233 Free PMC article.
Antidepressants for agitation and psychosis in dementia.Cochrane Database Syst Rev. 2011 Feb 16;(2):CD008191. doi: 10.1002/14651858.CD008191.pub2. Cochrane Database Syst Rev. 2011. PMID: 21328305 Review.
Antihypertensive withdrawal for the prevention of cognitive decline.Cochrane Database Syst Rev. 2016 Nov 1;11(11):CD011971. doi: 10.1002/14651858.CD011971.pub2. Cochrane Database Syst Rev. 2016. PMID: 27802359 Free PMC article. Review.
Cited by 12 articles
MEDREV (pharmacy-health psychology intervention in people living with dementia with behaviour that challenges): the feasibility of measuring clinical outcomes and costs of the intervention.BMC Health Serv Res. 2020 Mar 2;20(1):157. doi: 10.1186/s12913-020-5014-0. BMC Health Serv Res. 2020. PMID: 32122341 Free PMC article.
The Hyperactivity-Impulsivity-Irritiability-Disinhibition-Aggression-Agitation Domain in Alzheimer's Disease: Current Management and Future Directions.Front Pharmacol. 2019 Sep 27;10:1109. doi: 10.3389/fphar.2019.01109. eCollection 2019. Front Pharmacol. 2019. PMID: 31611794 Free PMC article. Review.
Pharmacologic Management of Agitation in Patients with Dementia.Curr Geriatr Rep. 2019 Mar;8(1):1-11. doi: 10.1007/s13670-019-0269-1. Epub 2019 Jan 22. Curr Geriatr Rep. 2019. PMID: 31341757 Free PMC article.
Management of Behavioral and Psychological Symptoms of Dementia.Curr Psychiatry Rep. 2019 Jul 1;21(8):66. doi: 10.1007/s11920-019-1049-5. Curr Psychiatry Rep. 2019. PMID: 31264056 Review.
Treatment Options for Agitation in Dementia.Curr Treat Options Neurol. 2019 Jun 24;21(7):30. doi: 10.1007/s11940-019-0572-3. Curr Treat Options Neurol. 2019. PMID: 31231784 Review.